Lucentis | search
Click here to view Lucentis news from 60+ newspapers.
Bookmark or Share- LUCENTIS® (ranibizumab) Mechanism of Action (MoA) for wAMDFind patient-friendly information below to explain to your patients how LUCENTIS is thought to work and what they may expect with the LUCENTIS® (ranibizumab injection). LUCENTIS is designed to block the vascular endothelial growth factor (VEGF) that builds up in the eye with wet age-related macular degeneration.
- Clinical Trial Efficacy & Results for wAMD - lucentisLearn about LUCENTIS® (ranibizumab injection) clinical trial results for wet AMD patients here. See full safety for more information.
- LUCENTIS® (ranibizumab) a Treatment Option for wAMD, DR & DME, mCNV, & RVOLearn about LUCENTIS (ranibizumab injection), a treatment option for wet AMD, diabetic macular edema (DME), diabetic retinopathy (DR), mCNV, & RVO. See full safety for more information.
- Dosing & Administration for wAMD | LUCENTIS® (ranibizumab)You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. Learn about the dosing and administration of LUCENTIS® (ranibizumab injection) 0.5 mg prefilled syringe. See full safety for more information.
- What to Expect During wAMD Treatment - lucentisLearn what to expect during your LUCENTIS® (ranibizumab) injection for wet AMD, including ways to help make sure your procedure experience is comfortable. See full safety for more information. Prescribing Information
More
